Sanofi SA is a multinational pharma company headquartered in Paris, France. Since 2013, this is the world's fifth company by prescribed drug sales. Founded back in 1973, the company was re-structured and re-branded as Sanofi-Aventis in 2004, after the merger of Aventis and Sanofi-Synthélabo, each of both being a result of previous mergers. In May 2011, the company was renamed to Sanofi. The company works in the following fields: cardiovascular system, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines.
Sanofi concluded a few successful acquisitions, the largest being Zentiva, Shantha Biotechnics, Chattem, Medley Pharmaceuticals Ltd., Genzyme, Globalpharma, and Bioverativ.
In Q1 2020, Sanofi's net profit rose by 47% to reach €1.68B, compared to €1.14B in Q1 2019. The earnings soared by 6.90% to €8.973B, or 6.60% currency rate adjusted. The boost occurred thanks to Dupixent, a drug used for eczema and asthma treatment. Dupixent sales skyrocketed by 129.80% to reach €776M.
Meanwhile, the earnings per share soared by 15.60% (no currency rate adjustment) and is now €1.63. Sanofi is still expecting the EPS to rise by 5% more by the end of 2020. Finally, the company's market cap increased by 14.60% over the last month, to reach €111.50B.
Now you will always be aware of which stocks are more profitable to invest in